Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.
Read the full articleYou might also wanna read
Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development
Even the biggest future blockbuster drugs can be prematurely abandoned.
statnews.com·6mo ago
Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows
In this week’s Optimizer, we take a look at how health tech companies are starting to incorporate features ‘built for GLP-1’ users.
theverge.com·1mo ago
3 High Growth GLP-1 Biotech Winners to Buy in July
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lowe
GLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer
The post GLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer appeared first on European Medical Journal .
Sciwind has two Western partners for its obesity drug, but is open to more
Sciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet.
endpoints.news·28d ago
New GLP-1 Drug Promotes Weight Loss in Obesity
A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to an 11 percent reduction in body
Comments
Sign in to join the conversation.
No comments yet. Be the first.